{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:48:24Z","timestamp":1789321704322,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HV23C0053"],"award-info":[{"award-number":["HV23C0053"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Korea Ministry of Trade Industry and Energy","doi-asserted-by":"publisher","award":["20014911"],"award-info":[{"award-number":["20014911"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.vaccine.2024.04.054","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T16:17:02Z","timestamp":1715012222000},"page":"3505-3513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-6259","authenticated-orcid":false,"given":"Jooyoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-5987","authenticated-orcid":false,"given":"Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10127","key":"10.1016\/j.vaccine.2024.04.054_b0005","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.vaccine.2024.04.054_b0010","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1016\/j.vaccine.2016.07.025","article-title":"A decade of adaptation: regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006\u20132016)","volume":"34","author":"Palkonyay","year":"2016","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2024.04.054_b0015","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1016\/j.vaccine.2017.08.088","article-title":"Data and product needs for influenza immunization programs in low- and middle-income countries: rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines","volume":"35","author":"Neuzil","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.04.054_b0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of protection against influenza infection in humans\u2013on the path to a universal vaccine?","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.054_b0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.vaccine.2017.11.061","article-title":"Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23\u201324 August 2016","volume":"36","author":"Ortiz","year":"2018","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2024.04.054_b0030","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/17460441.2020.1801629","article-title":"Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection","volume":"15","author":"Jang","year":"2020","journal-title":"Expert Opin Drug Discov"},{"issue":"8","key":"10.1016\/j.vaccine.2024.04.054_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/v14081684","article-title":"Progress towards the development of a universal influenza vaccine","volume":"14","author":"Wang","year":"2022","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.vaccine.2024.04.054_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075460","article-title":"Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.vaccine.2024.04.054_b0045","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1128\/JVI.00823-14","article-title":"Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice","volume":"88","author":"Kim","year":"2014","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.054_b0050","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5284","key":"10.1016\/j.vaccine.2024.04.054_b0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic analysis of antigen-specific T lymphocytes","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.054_b0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2024.04.054_b0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/hum.2013.235","article-title":"Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field","volume":"25","author":"Majhen","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"32","key":"10.1016\/j.vaccine.2024.04.054_b0070","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.vaccine.2024.04.054_b0075","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.vaccine.2016.08.066","article-title":"Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1","volume":"34","author":"Cheng","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2024.04.054_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/v13081493","article-title":"Nonhuman adenoviral vector-based platforms and their utility in designing next generation of vaccines for infectious diseases","volume":"13","author":"Alhashimi","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.054_b0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.gt.3302859","article-title":"Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon","volume":"14","author":"Kurachi","year":"2007","journal-title":"Gene Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2024.04.054_b0090","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.ymthe.2022.08.002","article-title":"Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2","volume":"30","author":"Dicks","year":"2022","journal-title":"Mol Ther"},{"issue":"15","key":"10.1016\/j.vaccine.2024.04.054_b0095","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1128\/JVI.79.15.9694-9701.2005","article-title":"Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity","volume":"79","author":"Lemckert","year":"2005","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.vaccine.2024.04.054_b0100","doi-asserted-by":"crossref","first-page":"12009","DOI":"10.1128\/JVI.01749-06","article-title":"Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity","volume":"80","author":"Thorner","year":"2006","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2024.04.054_b0105","article-title":"Adenovirus specific pre-immunity induced by natural route of infection does not impair transduction by adenoviral vaccine vectors in mice","volume":"10","author":"de Andrade","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.054_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003548","article-title":"Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice","volume":"3","author":"Croyle","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.04.054_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.01.002","article-title":"Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus","author":"Kim","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2024.04.054_b0120","unstructured":"Faqi AS. A comprehensive guide to toxicology in nonclinical drug development. 2nd ed. Amsterdam: Academic Press is an imprint of Elsevier; 2017. xiii, 971 pages."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400481X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400481X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T16:56:28Z","timestamp":1716828988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2400481X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0264410X2400481X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}